{"id":"https://openalex.org/W2145840924","doi":"https://doi.org/10.1161/01.str.30.5.986","title":"Safety and Tolerability of GV150526 (a Glycine Site Antagonist at the N -Methyl- d -Aspartate Receptor) in Patients With Acute Stroke","display_name":"Safety and Tolerability of GV150526 (a Glycine Site Antagonist at the N -Methyl- d -Aspartate Receptor) in Patients With Acute Stroke","alternate_titles":[],"publication_year":1999,"publication_date":"1999-05-01","ids":{"openalex":"https://openalex.org/W2145840924","doi":"https://doi.org/10.1161/01.str.30.5.986","mag":"2145840924","pmid":"https://pubmed.ncbi.nlm.nih.gov/10229732"},"language":"en","primary_location":{"id":"doi:10.1161/01.str.30.5.986","doi":"https://doi.org/10.1161/01.str.30.5.986","is_oa":false,"landing_page_url":"https://doi.org/10.1161/01.str.30.5.986","pdf_url":null,"source":{"id":"https://openalex.org/S62532593","display_name":"Stroke","issn_l":"0039-2499","issn":["0039-2499","1524-4628"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Stroke","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2145840924"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111766478","display_name":"Alexander G. Dyker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801120601","display_name":"Western Infirmary","ror":"https://ror.org/02e22bh87","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2801120601"]}],"countries":["GB"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Alexander G. Dyker","raw_affiliation_strings":["From the Acute Stroke Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Acute Stroke Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland","institution_ids":["https://openalex.org/I2801120601"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108080058","display_name":"Kennedy R. Lees","orcid":"https://orcid.org/0000-0002-9783-1227","observed_orcids":["https://orcid.org/0000-0002-9783-1227"]},"institutions":[{"id":"https://openalex.org/I2801120601","display_name":"Western Infirmary","ror":"https://ror.org/02e22bh87","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2800201399","https://openalex.org/I2801120601"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kennedy R. Lees","raw_affiliation_strings":["From the Acute Stroke Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Acute Stroke Unit, University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, Scotland","institution_ids":["https://openalex.org/I2801120601"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5111766478"],"corresponding_institution_ids":["https://openalex.org/I2801120601"],"apc_list":null,"apc_paid":null,"fwci":5.4373,"has_fulltext":true,"cited_by_count":56,"citation_normalized_percentile":{"value":0.95894632,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"30","issue":"5","first_page":"986","last_page":"992"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.9014000296592712,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.9014000296592712,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13796","display_name":"Neuroprotection in Cerebral Ischemia","score":0.08489999920129776,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glycine-site-antagonists","display_name":"glycine site antagonists","score":0.9259999990463257},{"id":"https://openalex.org/keywords/nmda-receptor","display_name":"NMDA receptor","score":0.949999988079071},{"id":"https://openalex.org/keywords/acute-stroke","display_name":"acute stroke","score":0.8299999833106995},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.9879999756813049},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.8970000147819519},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9810000061988831},{"id":"https://openalex.org/keywords/liver-function-tests","display_name":"liver function tests","score":0.6880000233650208},{"id":"https://openalex.org/keywords/bilirubin","display_name":"bilirubin","score":0.7990000247955322},{"id":"https://openalex.org/keywords/aminotransferases","display_name":"transaminases","score":0.9879999756813049},{"id":"https://openalex.org/keywords/central-nervous-system-adverse-effects","display_name":"central nervous system adverse effects","score":0.6510000228881836},{"id":"https://openalex.org/keywords/barthel-index","display_name":"Barthel Index","score":0.7239999771118164},{"id":"https://openalex.org/keywords/nihss","display_name":"NIHSS","score":0.8899999856948853},{"id":"https://openalex.org/keywords/middle-cerebral-artery-occlusion","display_name":"middle cerebral artery occlusion","score":0.7699999809265137}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9137125015258789},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8841859102249146},{"id":"https://openalex.org/C2780645631","wikidata":"https://www.wikidata.org/wiki/Q671554","display_name":"Stroke (engine)","level":2,"score":0.602510929107666},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5886441469192505},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.5864118337631226},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5820735096931458},{"id":"https://openalex.org/C25498285","wikidata":"https://www.wikidata.org/wiki/Q1981368","display_name":"Neuroprotection","level":2,"score":0.5344345569610596},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.338994562625885},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06349200010299683},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000208","descriptor_name":"Acute Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000410","descriptor_name":"Alanine Transaminase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000469","descriptor_name":"Alkaline Phosphatase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D001663","descriptor_name":"Bilirubin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002561","descriptor_name":"Cerebrovascular Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004562","descriptor_name":"Electrocardiography","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005723","descriptor_name":"gamma-Glutamyltransferase","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018684","descriptor_name":"Glycine Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018684","descriptor_name":"Glycine Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018684","descriptor_name":"Glycine Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1161/01.str.30.5.986","doi":"https://doi.org/10.1161/01.str.30.5.986","is_oa":false,"landing_page_url":"https://doi.org/10.1161/01.str.30.5.986","pdf_url":null,"source":{"id":"https://openalex.org/S62532593","display_name":"Stroke","issn_l":"0039-2499","issn":["0039-2499","1524-4628"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Stroke","raw_type":"journal-article"},{"id":"pmid:10229732","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10229732","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Stroke","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W10084778","https://openalex.org/W2000543257","https://openalex.org/W2003066583","https://openalex.org/W2009476128","https://openalex.org/W2052255804","https://openalex.org/W2076593694","https://openalex.org/W2088299968","https://openalex.org/W2169742106","https://openalex.org/W2409354322","https://openalex.org/W4307833091"],"related_works":["https://openalex.org/W2044546810","https://openalex.org/W4244304671","https://openalex.org/W2005395035","https://openalex.org/W2131673806","https://openalex.org/W2033732374","https://openalex.org/W2085729209","https://openalex.org/W2109708478","https://openalex.org/W3099009565","https://openalex.org/W2049788464","https://openalex.org/W1990305593"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"PURPOSE:":[2],"GV150526":[3,43,75,179,284],"is":[4,16,285],"a":[5,17,84,248],"novel":[6],"glycine":[7],"site":[8],"antagonist":[9],"at":[10,37,129,263,318],"the":[11,33,38,64,98,115,170,184,216,226,242,260,269],"N-methyl-D-aspartate":[12],"receptor":[13],"complex.":[14],"It":[15],"potent":[18],"neuroprotective":[19,135,288],"agent":[20],"in":[21,32,76,91,207,213,251,258,312],"animal":[22],"models":[23],"of":[24,48,58,69,74,97,102,158,194,222,237,272],"stroke,":[25],"including":[26],"permanent":[27],"middle":[28],"cerebral":[29],"artery":[30],"occlusion":[31],"rat.":[34],"Unlike":[35],"antagonists":[36],"glutamate":[39],"ligand":[40],"binding":[41],"site,":[42],"appears":[44],"to":[45,62,133,147,169,303,306],"be":[46,304],"free":[47],"hemodynamic":[49,199,298],"and":[50,67,71,155,235,253,278,309,322],"central":[51,195,294],"nervous":[52,196,295],"system":[53,197,296],"adverse":[54,200],"effects.":[55,299],"The":[56,142],"purpose":[57],"this":[59],"study":[60,89,143,171],"was":[61,83,122,144,180,191],"assess":[63],"safety,":[65],"tolerability,":[66],"pharmacokinetics":[68],"loading":[70,100,117,228],"maintenance":[72,125,218,245,320],"infusions":[73,126,128],"patients":[77,166,176,186,224,239,255],"with":[78,203,215,290],"acute":[79],"stroke.":[80],"METHODS:":[81],"This":[82],"randomized,":[85],"placebo-controlled,":[86],"parallel-group,":[87],"ascending-dose":[88],"conducted":[90],"2":[92],"phases.":[93],"In":[94,112],"part":[95,113,120],"A":[96,121],"study,":[99],"doses":[101,219],"50,":[103],"100,":[104],"200,":[105],"400,":[106],"or":[107,198,297],"800":[108],"mg":[109,233],"were":[110,139,162,167,211,276,324],"administered.":[111],"B,":[114],"maximum":[116],"dose":[118,229,246],"from":[119],"followed":[123,230],"by":[124,183,231],"(5":[127],"12-hour":[130],"intervals),":[131],"aiming":[132],"maintain":[134],"levels.":[136],"Safety":[137],"data":[138,152],"collected":[140],"throughout.":[141],"not":[145],"designed":[146],"test":[148],"efficacy,":[149],"but":[150],"outcome":[151],"(Barthel":[153],"Index":[154],"National":[156],"Institutes":[157],"Health":[159],"Stroke":[160],"Scale)":[161],"collected.":[163],"RESULTS:":[164],"Sixty-six":[165],"recruited":[168],"over":[172],"11":[173],"months;":[174],"18":[175],"received":[177,188,241],"placebo.":[178,204],"well":[181],"tolerated":[182],"48":[185],"who":[187,240],"it.":[189],"There":[190],"no":[192,291,325],"excess":[193],"events":[201],"compared":[202],"Minor":[205],"abnormalities":[206],"liver":[208],"function":[209],"tests":[210],"observed":[212,317],"association":[214],"higher":[217],"tested.":[220],"Four":[221],"7":[223],"receiving":[225],"800-mg":[227],"400":[232],"BID":[234,244],"1":[236],"6":[238],"200-mg":[243],"showed":[247],"small":[249],"rise":[250],"bilirubin,":[252],"3":[254],"had":[256],"increases":[257],"transaminases;":[259],"mean":[261],"values":[262],"72":[264],"hours":[265],"remained":[266],"under":[267],"twice":[268],"upper":[270],"limit":[271],"normal.":[273],"These":[274],"changes":[275],"asymptomatic":[277,310],"resolved":[279],"within":[280],"10":[281],"days.":[282],"CONCLUSIONS:":[283],"an":[286],"emerging":[287],"agent,":[289],"apparent":[292],"significant":[293],"Dose-limiting":[300],"effects":[301],"appear":[302],"restricted":[305],"mild":[307],"transient":[308],"rises":[311],"bilirubin":[313],"and/or":[314],"transaminases,":[315],"primarily":[316],"high":[319],"doses,":[321],"there":[323],"findings":[326],"that":[327],"should":[328],"preclude":[329],"further":[330],"clinical":[331],"development.":[332]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2145840924","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":5},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
